Expanding local production and changing CMO companies...The pharmaceutical and bio industries are busy preparing measures to announce at least 25% tariffs on Trump's drugs
Feb 19, 2025
|
Domestic pharmaceutical and bio companies are also busy preparing countermeasures against the risks caused by such tariff policies.
Celltrion announced on its website on the 19th that it has established an optimal response system regarding the possibility of imposing drug tariffs. The company's products, which are scheduled to be sold in the U.S. this year, have completed about nine months of inventory transfer as of the end of January, minimizing the impact on sales in the U.S. He also said that when tariffs are imposed, the company is focusing on exporting raw materials that have less tax burden than finished drugs, adding that if necessary, it will expand the production of finished drugs in the region.
SK Biopharmaceuticals is reportedly considering various measures such as changing its consignment producer. SK Biopharmaceuticals' epilepsy treatment 'Senovamate' will be exported to the United States through Canadian-based consignment production (CMO) companies, and if tariffs on Canada are confirmed in the future, it plans to consider using local CMO companies in the United States. Samsung Biologics, Samsung Bioepis, and Daewoong Pharmaceutical are also closely watching the Trump administration's tariff policy and preparing for it.
Meanwhile, Yuhan Corporation, which exported technology to Janssen last year for $1.255 billion (about 1.8 trillion won) for the global development and sales rights of Lecraza, a treatment for non-small cell lung cancer, is relatively free from risk.
This article was translated by Naver AI translator.
